Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1561-1568

  Lee, Hee Jin ^a   Seo, An Na ^b   Park, So Yeon ^b,c   Kim, Joo Young ^a   Park, Ji Young ^a   Yu, Jong Han ^a   Ahn, Jin Hee ^a   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COPY NUMBER VARIATION; DNA METHYLATION; ENZYME MECHANISM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; BASAL CELL CARCINOMA; CANCER GRADING; CANCER STAGING; CLASSIFICATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY; YOUNG ADULT;

ADULT; AGED; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84898845401     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3456-x     Document Type: Article

References (21)

1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-67.
2. Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, et al. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer. 2011;2:870-9.
3. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29:2013-23.
4. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18:1855-62.
5. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823:850-60.
6. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: A chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9:R23. (Pubitemid 350215164)
7. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95.
8. Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol. 2011;24:794-800.
9. Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 2012;14:R115.
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-55. (Pubitemid 40812628)
11. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400-4.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74. (Pubitemid 39100473)
13. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-76. (Pubitemid 351413917)
14. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104:20007-12.
15. Massabeau C, Sigal-Zafrani B, Belin L, Savignoni A, Richardson M, Kirova YM, et al. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? Breast Cancer Res Treat. 2012;134:259-66.
16. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2012;105:773-9.
17. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res. 2005;3:655-67. (Pubitemid 43042995)
18. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085-94.
19. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011;17:5275-86.
20. Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res. 2012;14:208.
21. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res Phila. 2010;3:1361-4.